Cancer Photodiagnosis and Photodynamic Therapy
A special issue of Bioengineering (ISSN 2306-5354).
Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 4407
Special Issue Editor
Special Issue Information
Dear Colleagues,
A successful cancer treatment hinges on accurate diagnosis, precise tumor resection and targeted therapy with minimum normal tissue toxicity. Used in combination with non-ionizing radiation, photodiagnostic probes and photosensitizers with little dark toxicity are being developed to improve cancer treatment outcomes. Three fluorescent probes including methylene blue, fluorescein and indocyanine green have been used in the clinic for over half a century to probe tissue perfusion, visualize angiography and facilitate tumor resection. Two most recent FDA-approved intraoperative probes are 5-aminolevulinic acid and pafolacianine. Different from the old fluorescent probes that highlight tumors solely based on the passive diffusion, two new FDA approvals and more under development make tumors visible to surgeons, thereby enabling fluorescence image-guided tumor resection, by revealing tumor-associated metabolic alterations. Since the first photosensitizer photofrin was approved by the FDA in 1995, about a dozen photosensitizers have received regulatory approvals throughout the world. These photo-active drugs are now commonly used for the treatment of superficial skin cancers and other types of cancer. The use of these photodiagnostic and photosensitizing drugs depends on compatible light sources, optical fibers and imaging systems. It is the combination of photoactive drug development and the engineering of companion optical devices that makes cancer photodiagnosis and photodynamic therapy a clinical success. This Special Issue of Bioengineering is to celebrate the success of this multidisciplinary research and development, tackle current issues in the field, and foresee future developments to expand its application in oncology.
Prof. Dr. Bin Chen
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- photodiagnostic
- cancer treatment
- Photodynamic Therapy
